

EPIDEMIOLOGICAL INSIGHTS (OR, WHY DOES CKD CAUSE HEART FAILURE?)

Colin Baigent Professor of Epidemiology

Director, MRC Population Health Research Unit; Deputy Director, Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford, UK

Disclosure of interests

Unrestricted grant provided by Novartis to the University of Oxford (study sponsor) to conduct the UK-HARP-3 trial of sacubitril/valsartan vs irbesartan in patients with CKD (Co-PI)




Presentation overview

- Epidemiological evidence that CKD is associated with an increased risk of heart failure (and vice versa)
- Potential problems in interpreting the evidence for risk factors for heart failure in CKD
- Suggested framework for conceptualising risk factors for heart failure in the context of CKD
- Contribution from <u>intrinsic risk factors</u> (defined as those that arise as a direct consequence of CKD)
- Contribution from <u>extrinsic risk factors</u> (defined as <u>causal</u> risk factors that are not a direct result of CKD)
- Implications for prevention of heart failure in CKD



Cumulative incidence of heart failure by eGFR in 14,800 ARIC study participants¹






KDIGO Controversies Conference on Heart Failure in CKD

May 25-28, 2017 | Athens, Greece

¹Kottgen *et al.* JASN 2007; 18:1307-15

Echocardiographic findings from 700 children¹ and 3500 adults² with CKD






Problems in interpreting observational studies among patients with CKD

- Kidney disease may distort associations between exposures and CV outcomes
 - Example: LDL cholesterol and CHD
- CVD is highly prevalent, but (a) may be subclinical, and (b) atherosclerotic and structural heart disease co-exist, complicating interpretation
 - Example: BP and vascular events
- Conclusion: assessment of <u>causation</u> by risk factors for heart failure in CKD should be informed by:
 - evidence in those <u>without CKD</u> (in whom reverse causality is less problematic)
 - separate consideration of atherosclerotic and non-atherosclerotic disease
 - Studies in which confounding can be minimised eg, RCTs and Mendelian Randomization studies




Association between cholesterol and risk of CHD in 350,000 healthy men¹






Inverse association between cholesterol and RR for CV mortality in dialysis patients¹



¹Baigent et al. Seminars in Dialysis 2007; 20:498-503



SHARP: reducing LDL cholesterol prevents major vascular events in CKD¹



¹ Baigent C et al, for SHARP investigators. Lancet 2011; 377:


KDIGO Controversies Conference on Heart Failure in CKD

May 25-28, 2017 | Athens, Greece




2181-92

Meta-analysis of 1 m healthy adults in 61 prospective studies: association of SBP with CHD¹





SHARP trial: association between systolic BP and MAJOR VASCULAR EVENTS (A) overall and (B) subdivided by evidence of prior CVD¹





KDIGO Controversies Conference on Heart Failure in CKD


May 25-28, 2017 | Athens, Greece

Definitions

- Intrinsic risk factors: exposures that arise as a direct consequence of CKD
- Extrinsic risk factors: known causes of heart failure that are <u>NOT</u> a direct consequence of CKD




Suggested framework for the causation of heart failure in patients with CKD





INTRINSIC RISK FACTORS: Heart failure mediated through myocardial ischaemia






INTRINSIC RISK FACTORS and the risk of coronary heart disease (CHD)

- Blood pressure
- Dyslipidaemia
 - LDL cholesterol
 - Triglycerides
 - Lp(a)
- Inflammation



Meta-analysis of 1 m healthy adults in 61 prospective studies: association of SBP with CHD¹





Genetic risk scores and selected CV outcomes¹

Phenotype	Consortium	Total N or Cases/ controls	SBP		DB	DBP	
			Effect/ mmHg	Р	Effect/ 1mmHg	Р	
Heart							
CHD	CARDIoGRAM plus4D	63,746/130,681	1.042	10 ⁻⁴⁴	1.069	10 ⁻³⁸	
Heart failure	CHARGE	2,526/18,400	1.021	0.03	1.035	0.02	
LV wall thickness (cm)	CHARGE	11,311	0.004	10 ⁻⁸	0.007	10 ⁻⁸	



¹ Ehret et al. Nature Genetics 2016; 48: 1171-84

Genetic risk scores for lipids and CHD

	CHD (incident/prevalent)		CHD (incident	t only)	
Allele score	Odds ratio (95% Cl)	P-value	Odds ratio (95% CI)	P-value	
HDL cholesterol					
Unrestricted (48 SNPs)	0.53 (0.40-0.70)	8.8 x 10 ⁻⁶	0.68 (0.47-0.97)	0.032	
Restricted (19 SNPs)	0.91 (0.42-1.98)	0.817	1.33 (0.49-3.59)	0.579	
Log Triglycerides	KV				
Unrestricted (67 SNPs)	1.62 (1.24-2.11)	3.7 x 10 ⁻⁴	1.59 (1.15-2.20)	5.1 x 10 ⁻³	
Restricted (27 SNPs)	1.61 (1.00-2.59)	0.05	1.63 (0.91-2.91)	0.098	
LDL cholesterol					
Unrestricted (42 SNPs)	1.78 (1.58-2.01)	2.0 x 10 ⁻²¹	1.43 (1.24-1.66)	9.7 x 10 ⁻⁷	
Restricted (19 SNPs)	1.92 (1.68-2.19)	4.6 x 10 ⁻²²	1.49 (1.26-1.75)	1.6 x 10 ⁻⁶	

¹ Holmes M et al. Eur Heart J 2015; 36: 539-550




Characteristic serum lipid distribution at different stages of CKD¹

	LDL-C	sdLDL	TRG	HDL-C	Lp(a)
Predialysis CKD (Stages 3-4)	↔ ^{OR} ↓	Ť	1	Ļ	↑ *
Nephrotic syndrome (Stages 3-4)	Ť	Ť		↓ OR ↔ OR ↑	↑
Hemodialysis (Stage 5)	↔ or ↓) \ `	Ť	Ļ	↑
Peritoneal dialysis (Stage 5)		Ť	Ť	Ļ	Ť
Renal transplantation (Stage 5)	Ť	Ť	Ť	Ť	1^{*}

^{*} Mainly in individuals with high-molecular-weight apolipoprotein(a) phenotypes. Tsimihodimos V et al. *Am J Nephrol*. 2008;28(6):958 973.



Mendelian Randomization: potential role for $Lp(a)^{1}$



variant allele, or two variant alleles) with the risk of coronary disease, as measured with the use of "floating absolute risks" which summarize the sampling variation for the three genotype scores without the se-


lection of an arbitrary baseline genotype score. The vertical lines indicate 95% confidence intervals.

- MR studies show that Lp(a) is a cause of CHD¹
- BUT, risk of increased Lp(a) in general population is for lowmolecular weight isoforms of Lp(a), whilst in CKD it is highmolecular weight isoforms that are increased

¹ Clarke et al, for the PROCARDIS investigators. NEJM 2009; 361: 2518-28



Long term follow up of the WOSCOPS trial: lowering LDL cholesterol prevents heart failure





KDIGO Controversies Conference on Heart Failure in CKD

May 25-28, 2017 | Athens, Greece

Ford et al. Circulation 2016; 133:1073-80

Markers of inflammation: IL6R is implicated in the causation of CHD




Figure 2: IL6R genotypes and risk of coronary heart disease


Data are shown for 51441 cases and 136226 controls. The odds ratio per minor allele was 0.966 (95% Cl 0.950-0.982, p= 4.5×10^{-5}). Details of the genotypes studied are provided in appendix p 12. Error bars show 95% Cl. *Reference group (represented by a square with in arbitrary fixed size).

Among markers of inflammation (CRP, fibrinogen, IL-6, soluble IL6R), genetic risk score experiment shows that the IL6R pathway is involved in causation of CHD¹

¹ IL6R Genetics Consortium Emerging Risk Factors Collaboration. Lancet 2012; 379: 1205-13




Suggested framework for the causation of heart failure in patients with CKD





Evidence that raised blood pressure is a cause of heart failure^{1,2}





Genetic risk scores and selected CV outcomes¹


Phenotype	Consortium	Total N or Cases/ controls	SBP		DB	DBP	
			Effect/ mmHg	Р	Effect/ 1mmHg	Р	
Heart							
CHD	CARDIoGRAM plus4D	63,746/130,681	1.042	10 ⁻⁴⁴	1.069	10 ⁻³⁸	
Heart failure	CHARGE	2,526/18,400	1.021	0.03	1.035	0.02	
LV wall thickness (cm)	CHARGE	11,311	0.004	10 ⁻⁸	0.007	10 ⁻⁸	



¹ Ehret et al. Nature Genetics 2016; 48: 1171-84

Evidence that anaemia is a cause of heart failure¹

Meta-analysis of ESA trials show reduced hospitalization for heart failure




¹Kotecha at al. Am Heart J 2011; 161: 822-831e2



KDIGO Controversies Conference on Heart Failure in CKD

May 25-28, 2017 | Athens, Greece

Lack of evidence that increasing haemoglobin reduce LV mass¹ or risk of heart failure hospitalisation² in CKD





RED-HF: No effect of darbepoietin alfa on heart failure hospitalisation¹


- RED-HF trial
- 2278 patients with systolic heart failure (HFrEF)
- Darbepoietin alfa vs placebo
- Median Hb 13.0 vs 11.5 g/dL
- Mean f.u. 28 months

¹Swedberg K et al. for the RED-HF group. NEJM 2013; 368: 1210-9



KDIGO Controversies Conference on Heart Failure in CKD May 25-28, 2017 | Athens, Greece

D Death from Cardiovascular Causes or First Hospitalization for Worsening Heart Failure




No. at Risk										
Placebo	1142 956	818	695	591	497	395	290	211	154	92
Darbepoetin alfa	1136 975	855	712	581	473	385	281	212	161	101

Associations between neurohumoral activation (sympathetic tone) and (a) CHD or (b) heart failure

- Heart rate (HR) independent risk factor for CV outcomes
- Inhibition of the I_f channel with ivabradine reduces HR (but not contractility)
- SHIFT trial (6558 patients with systolic HF), ivabradine reduced risk of heart failure hospitalisation (16% vs 21%; P<0.0001- right panel)¹
- SIGNIFY trial (19,102 patients with stable CHD), ivabradine had no effect on risk of MI (4.1% vs 3.9%; P=0.43)


SHIFT trial: Hospitalisation for worsening heart failure



¹Swedberg K et al. for SHIFT investigators. Lancet 2010; 376:875-85 ²Fox K et al for the SIGNIFY investigators. NEJM 2014; 371: 1091-99



EVOLVE: effect of cinacalcet on risk of heart failure¹



No. at Risk


 Placebo
 1935 1842 1753 1652 1565 1478 1404 1333 1264 1216 1159 1110 1054 737 464 129

 Cinacalcet
 1948 1873 1798 1712 1649 1579 1499 1422 1357 1301 1242 1176 1115 769 452 128

¹ The EVOLVE Trial Investigators^{*} NEJM 2012; 367:2482-2494



Suggested framework for the causation of heart failure in patients with CKD






INTRINSIC RISK FACTORS and risk of CKD progression (ie, loss of glomerular filtration)

- Blood pressure: ↑BP associated with ↑progression, BUT genetic risk scores (GRS) suggest causal association for ↑ uACR (not ↓ eGFR)
- Increased glomerular pressure/hyperfiltration: EMPA-REG demonstrated that empagliflozin↓progression, as have trials in which ↓uACR (+ ↓ BP) reduce progression



Suggested framework for the causation of heart failure in patients with CKD





EXTRINSIC RISK FACTORS and risk of (a) CHD (b) heart failure & (c) CKD progression

	CHD	Heart failure	CKD progression
Diabetes mellitus	RR = 2.0 (1.8-2.2) ¹	RR = 1.9 (1.5-2.3) ² RR = 1.6 (1.4-1.7) ³	Renal death RR = 3.0 (2.4-3.8) ⁴
Higher body mass index	RR per 5 kg/m ² = 1.4 (1.3-1.4) ⁵	RR per 5 kg/m ² = 1.9 (1.6-2.2) ⁵	ESRD: RR* = 6.1 (5.0-7.5) ⁶ CKD stages 4-5: RR = 1.9 (1.9-2.0) ⁷
Cigarette smoking	RR = 1.5 (1.3-1.8) for atherosclerotic events in CKD patients ⁸	RR = 1.6 (1.4-1.8) ²	RR ↑ in some observational studies ⁷ ; no effect on progression (serial eGFRs) in SHARP ⁸

* BMI 30-35 vs 18.5-25 kg/m²

¹ ERFC Lancet 2010; 375: 2215-2222; ² He et al. Arch Intern Med 2001; 161: 996-1002; ³ Shah AD et al. Lancet Diab Endo 2015; 3: 105-13; ⁴ Emerging Risk Factors Collaboration NEJM 2011; 364: 829-41; ⁵ Whitlock et al. Lancet 2009; 9669: 1083-1096; ⁶ Hsu et al. Ann Intern Med, AJKD 2006; 144(1): 21-8; ⁷ Herrington et al. PlosONE 2017; 12(3): e0173515; ⁸ Staplin et al. AJKD 2016; 68: 371-80



SUMMARY: aetiological relevance of INTRINSIC RISK FACTORS

	CHD	Heart failure	CKD progression
Blood pressure	+++	+++	+/-
Dyslipidaemia	+	+	-
Anaemia/ iron- deficiency	+/-		-
Neurohumoral activation	+/-	++	++
Albuminuria	+/-	+/-	+/-
Mineral Bone Disease	+/-	+/-	+/-
Inflammation	+	+/-	+/-




SUMMARY: aetiological relevance of EXTRINSIC RISK FACTORS (by definition, causal)

	CHD	Heart failure	CKD progression
Diabetes	+++	+++	+++
Higher body mass index	++		++
Cigarette smoking	+++	+++	+/-
	- NV		



Suggested framework for the causation of heart failure in patients with CKD





Conclusions: priorities for prevention of heart failure in CKD, based on current knowledge

- Treatments for extrinsic risk factors likely to be effective:
 - Quitting cigarette smoking
 - Improved diabetic control
 - Avoidance of overnutrition
- Treatments for intrinsic risk factors (based on current evidence) – treat now or conduct RCTs.
 - Intensive blood pressure reduction
 - Reduce neurohormonal activation (eg, RAAS blockade, MRAs)
 - Reduce sympathetic activity (eg, beta-blockers)
- Modification of other intrinsic risk factors more speculative and requires new RCT or convincing genetic risk score evidence



Acknowledgements





I gratefully acknowledge the generous support of the UK Medical Research Council

